Cytokine profile in critically ill patients and/or injured persons with secondary sepsis – influence of different pathogens

Snežana Đukić; Aleksandar Pavlović; Aleksandra Ilić; Aleksandar Božović; Gojko Igrutinović; Miljana Nikolić; Mirjana Vujačić; Ivan Stanojević

doi:10.2298/VSP230105054D

Snežana Đukić Clinical Hospital Center Kosovska Mitrovica, Department of Anesthesiology, Kosovska Mitrovica, Serbia
Aleksandar Pavlović University of Priština/Kosovska Mitrovica, Faculty of Medicine, Department of Surgery, Kosovska Mitrovica, Serbia
Aleksandra Ilić University of Priština/Kosovska Mitrovica, Faculty of Medicine, Department of Preventive Medicine, Kosovska Mitrovica, Serbia
Aleksandar Božović University of Priština/Kosovska Mitrovica, Faculty of Medicine, †Department of Surgery, Kosovska Mitrovica, Serbia
Gojko Igrutinović Clinical Hospital Center Kosovska Mitrovica, Department of Surgery, Kosovska Mitrovica, Serbia
Miljana Nikolić Health Center Kosovska Mitrovica, Kosovska Mitrovica, Serbia
Mirjana Vujačić Clinical Hospital Center Kosovska Mitrovica, Department of Infectology, Kosovska Mitrovica, Serbia
Ivan Stanojević Military Medical Academy, Institute for Medical Research, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP230105054D

Keywords: blood culture, critical illness, cytokines, prognosis, sepsis, treatment outcome

Abstract

Background/Aim. The role of the complex sepsis-related immune response has not been fully clarified and remains a subject matter of investigation. Nowadays, sepsis is considered a dynamic syndrome characterized by many, often antagonistic phenomena, ranging from hyperinflammation to anergy and immunoparalysis. The aim of the study was to determine, based on the level of pro- and anti-inflammatory mediators in critically ill patients with secondary sepsis, whether the cytokine profile differs according to the type of bacterial causative agent, as well as to assess the prognostic value regarding the outcome. The outcome measure was in-hospital mortality. Methods. Blood serum samples were taken from 125 critically ill patients admitted to the Surgical Intensive Care Unit with severe secondary sepsis as a consequence of peritonitis, pancreatitis, or trauma. The average age of the patients was 57.7 ± 17.3 years. Of the total number of patients, 84 (67.2%) were males, and 41 (32.8%) were females. The levels of pro-inflammatory interleukin (IL)-1α, IL-1β, IL-6, IL-8, IL-12р70, IL-17А, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IFN-γ-inducible protein-10 (IP-10), monocyte chemoattractant protein-1(MCP-1), macrophage inflammatory protein (MIP)-1α and MIP-1β, as well as anti-inflammatory mediators IL-4, IL-10, IL-13, IL-27, IL-31, and IL-33, were determined at three time intervals – on the day of admission (the first day) and then on the third and fifth day. The type of the bacterial causative agent was determined using standard microbiological analyses. Results. On the third day of measurement, significant differences in the cytokine levels regarding the nature of bacteremia were determined in all pro- and anti-inflammatory cytokines, except for IL-8. In general, the lowest levels were observed in patients with polymicrobial blood cultures. On the first and fifth days of measurement, no significant differences in the cytokine levels regarding the nature of bacteremia were found. The only significant predictor of the fatal outcome on the first measurement day was IL-17А, Area Under the Receiver Operating Characteristic (ROC) Curve (AUC) of 0.665 (95% confidence interval 0.519–0.791; р = 0.034) in the patients with secondary sepsis as a complication of peritonitis. Conclusion. According to the type of bacterial causative agent, the lowest levels of cytokines have been observed in patients with the polymicrobial blood culture. The low level of IL-17А on the first day of measurement is a good predictor of a fatal outcome in patients with peritonitis as an underlying condition of secondary sepsis. On the other hand, the levels of other cytokines correlated with the outcome only on the fifth day of measurement, and they were higher in survivors than in non-survivors.

References

Monneret G, Venet F. Sepsis-induced immune alterations moni-toring by flow cytometry as a promising tool for individualized therapy. Cytom B Clin Cytom 2016; 93(4): 376–86.

Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 2012; 72(6): 1491–501.

Surbatovic M, Veljovic M, Jevdjić J, Popovic N, Djordjevic D, Rada-kovic S. Immunoinflammatory response in critically ill patients: severe sepsis and/or trauma. Mediators Inflamm 2013; 2013: 362793.

Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306(23): 2594–605.

Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old cer-emony. Mol Med 2008; 14(1–2): 64–78.

Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166(11): 6952–63.

Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, et al. The late phase of sepsis is characterized by an increased mi-crobiological burden and death rate. Crit Care 2011; 15(4): R183.

Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, et al. Reactivation of multiple viruses in patients with sepsis. PLoS One 2014; 9(2): e98819.

Tsirigotis P, Chondropoulos S, Gkirkas K, Meletiadis J, Dimopoulou I. Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis. J Thorac Dis 2016; 8(5): E312–6.

Prucha M, Zazula R, Russwurm S. Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment? Arch Immu-nol Ther Exp (Warsz) 2017; 65(1): 37–49.

Pène F, Pickkers P, Hotchkiss RS. Is this critically ill patient im-munocompromised? Intensive Care Med 2016; 42(6): 1051–4. Erratum in: Intensive Care Med 2016; 42(6): 1106.

Shankar-Hari M. How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis? Crit Care 2017; 21(1): 125.

Surbatovic M, Grujic K, Cikota B, Jevtic M, Filipovic N, Romic P, et al. Polymorphisms of genes encoding tumor necrosis factor-alpha, interleukin-10, cluster of differentiation-14 and inter-leukin-1ra in critically ill patients. J Crit Care 2010; 25(3): 542.e1–8.

Martin S, Pérez A, Aldecoa C. Sepsis and immunosenescence in the elderly patient: a review. Front Med (Lausanne) 2017; 4: 20.

Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med 2016; 42(9): 1387–97.

Asehnoune K, Villadangos J, Hotchkiss RS. Understanding host-pathogen interaction. Intensive Care Med 2016; 42(13): 2084–6.

Antonakos N, Tsaganos T, Oberle V, Tsangaris I, Lada M, Pistiki A, et al. Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. Crit Care 2017; 21(1): 48.

Surbatovic M, Popovic N, Vojvodic D, Milosevic I, Acimovic G, Stojicic M, et al. Cytokine profile in severe Gram-positive and Gram-negative abdominal sepsis. Sci Rep 2015; 5: 11355.

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, An-nane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315(8): 801–10.

Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Fer-rer R, et al. Surviving Sepsis Campaign: International Guide-lines for Management of Sepsis and Septic Shock: 2016. In-tensive Care Med 2017; 43(3): 304–77.

Delano MJ, Ward PA. The immune system’s role in sepsis pro-gression, resolution, and long-term outcome. Immunol Rev 2016; 274(1): 330–53.

Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guide-lines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medi-cine. Chest 1992; 101(6): 1644–55.

Rhee C, Klompas M. New Sepsis and Septic Shock Definitions: Clinical Implications and Controversies. Infect Dis Clin North Am 2017; 31(3): 397–413.

Tamayo E, Fernández A, Almansa R, Carrasco E, Heredia M, La-jo C, et al. Pro- and anti-inflammatory responses are regulated simultaneously from the first moments of septic shock. Eur Cytokine Netw 2011; 22(2): 82–7.

Novotny AR, Reim D, Assfalg V, Altmayr F, Friess HM, Em-manuel K, et al. Mixed antagonist response and sepsis severity-dependent dysbalance of pro- and anti-inflammatory responses at the onset of postoperative sepsis. Immunobiology 2012; 217(6): 616–21.

Pickkers P, Kox M. Towards precision medicine for sepsis pa-tients. Crit Care 2017; 21(1): 11.

Pène F, Vincent JL, Martin-Loeches I. On the verge of using an immune toolbox in the intensive care unit? Intensive Care Med 2017; 43(8): 1154–6.

Mera S, Tatulescu D, Cismaru C, Bondor C, Slavcovici A, Zanc V, et al. Multiplex cytokine profiling in patients with sepsis. APMIS 2011; 119(2): 155–63.

Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007; 11(2): R49.

Jekarl DW, Kim JY, Lee S, Kim M, Kim Y, Han K, et al. Diag-nosis and evaluation of severity of sepsis via the use of bi-omarkers and profiles of 13 cytokines: a multiplex analysis. Clin Chem Lab Med 2015; 53(4): 575–81.

Mehra S, Tiwari AK, Aggarwal G, Mehta SP, Chauhan R, Rajvanshi C, et al. Diagnostic value of different interleukins and procalcitonin in critically ill patients admitted with sus-pected sepsis. Indian J Pathol Microbiol 2022; 65(1): 111–6.

Gao H, Evans TW, Finney SJ. Bench-to-bedside review: sepsis, severe sepsis and septic shock - does the nature of the infect-ing organism matter? Crit Care 2008; 12(3): 213.

Tang Y, Liao C, Xu X, Song H, Shi S, Yang S. Th1/Th2 cyto-kine profiles in G+/G- bacteremia in pediatric hematolo-gy/oncology patients. Pediatr Blood Cancer 2012; 58(1): 50–4.

Cohen J. A role for the micro-organism in the outcome from infection? A principle challenged. Crit Care Med 2011; 39(8): 2001–2.

Mosevoll KA, Skrede S, Markussen DL, Fanebust HR, Flaatten HK, Aßmus J, et al. Inflammatory Mediator Profiles Differ in Sepsis Patients With and Without Bacteremia. Front Immunol 2018; 9: 691.

Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, Moldawer LL, et al. Molecular characterization of the acute in-flammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immun 2003; 71(10): 5803–13.

Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34(2): 344–53.

Zahar JR, Timsit JF, Garrouste-Orgeas M, Français A, Vesin A, Descorps-Declere A, et al. Outcomes in severe sepsis and pa-tients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 2011; 39(8): 1886–95. Erratum in: Crit Care Med 2011; 39(10): 2392.

Bhavsar I, Miller CS, Al-Sabbagh M. Macrophage Inflammatory Protein-1 Alpha (MIP-1 alpha)/CCL3: As a Biomarker. In: Preedy V, Patel V, editors. General Methods in Biomarker Re-search and their Applications. Biomarkers in Disease: Meth-ods, Discoveries and Applications. 2015th ed. Dordrecht: Springer; 2015. p. 223–49.

De Pablo R, Monserrat J, Prieto A, Alvarez-Mon M. Role of cir-culating soluble chemokines in septic shock. Med Intensiva 2013; 37(8): 510–8. (English, Spanish)

Zambon M, Ceola M, Almeida-de-Castro R, Gullo A, Vincent JL. Implementation of the Surviving Sepsis Campaign guidelines for severe sepsis and septic shock: we could go faster. J Crit Care 2008; 23(4): 455–60.

Afuwape OO, Ayandipo OO, Kuti M, Adigun TA, Idowu OK. Tu-mor Necrosis Factor-Alpha and Interleukin-1 Alpha as Predic-tors of Survival in Peritonitis: A Pilot Study. Niger J Surg 2018; 24(2): 107–10.

Flierl MA, Rittirsch D, Gao H, Hoesel LM, Nadeau BA, Day DE, et al. Adverse functions of IL-17A in experimental sep-sis. FASEB J 2008; 22(7): 2198–205.

Freitas A, Alves-Filho JC, Victoni T, Secher T, Lemos HP, Sônego F, et al. IL-17 receptor signaling is required to control polymi-crobial sepsis. J Immunol 2009; 182(12): 7846–54.

Morrow KN, Coopersmith CM, Ford ML. IL-17, IL-27, and IL-33: A Novel Axis Linked to Immunological Dysfunction Dur-ing Sepsis. Front Immunol 2019; 10: 1982.

Ahmed Ali M, Mikhael ES, Abdelkader A, Mansour L, El Es-sawy R, El Sayed R, et al. Interleukin-17 as a predictor of sep-sis in polytrauma patients: a prospective cohort study. Eur J Trauma Emerg Surg 2018; 44(4): 621–6.

Tassinari M, Zannoli S, Farabegoli P, Pedna MF, Pierro A, Mastro-ianni A, et al. Rapid diagnosis of bloodstream infections in the critically ill: Evaluation of the broad-range PCR/ESI-MS technology. PLoS One 2018; 13(5): e0197436.